1. (1) A pharmacist may prescribe a drug or device for a legitimate medical purpose as allowed under this section for a person with whom the pharmacist has a patient-prescriber relationship.

2. (2) A pharmacist shall establish the patient-prescriber relationship through a documented patient evaluation that is adequate to:

   1. (a) establish diagnoses, if the drug or device is being prescribed pursuant to subsection (3)(b); and
   2. (b) identify underlying conditions and contraindications to the treatment.

3. (3) A pharmacist's prescribing authority is limited to drugs and devices that are prescribed for conditions that:

   1. (a) do not require a new diagnosis; or

   2. (b)

      1. (i) are minor and generally self-limiting;
      2. (ii) are diagnosed by or for which clinical decisions are made using a test that is waived under the federal clinical laboratory improvement amendments of 1988; or
      3. (iii) are patient emergencies.

4. (4) A pharmacist may:

   1. (a) prescribe only the drugs or devices for which the pharmacist is educationally prepared and for which competency has been achieved and maintained; and
   2. (b) bill only for assessment services that were necessary, based on the pharmacist's professional judgment, for the pharmacist's decision to prescribe a drug or device pursuant to this section.
5. (5) A pharmacist may not prescribe a controlled substance or an abortion-inducing drug as that term is defined in 50-20-703.

6. (6) A pharmacist prescribing a drug or device pursuant to this section shall:

   1. (a) recognize the limits of the pharmacist's knowledge and experience and consult with and refer to other health care providers as appropriate; and

   2. (b) maintain documentation sufficient to justify the care provided, including but not limited to the:

      1. (i) information collected as part of the patient record;
      2. (ii) prescription record;
      3. (iii) provider notification; and
      4. (iv) follow-up care plan.
7. (7) This section does not apply to a pharmacist who is operating within a collaborative pharmacy practice agreement.

History: En. Sec. 1, Ch. 322, L. 2023.